4DMT is initially focused on five clinical-stage product candidates in three therapeutic areas for both rare and large market diseases: ophthalmology, pulmonology, and cardiology (Fabry disease cardiomyopathy). 4DMT seeks to unlock the full potential of genetic medicines using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in 4DMT’s target candidates. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-86 or by email at BofA Securities, Inc., NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by email at Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200, or by email at or by accessing the SEC’s website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.ĤDMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: Goldman Sachs & Co. Copies of the registration statement can be accessed through the SEC’s website at The offering was made only by means of a prospectus. Securities and Exchange Commission (SEC) and was declared effective on April 15, 2022. Chardan acted as the lead manager for the offering.Ī registration statement relating to the shares sold in this offering was filed with the U.S. LLC, BofA Securities and Evercore ISI acted as the joint book-running managers for the offering. All of the shares in the offering were sold by 4D Molecular Therapeutics. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by 4D Molecular Therapeutics, were $138.0 million. The shares of common stock issued and sold in the offering include 1,125,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today the closing of an upsized underwritten public offering of 8,625,000 shares of its common stock at a public offering price of $16.00 per share. It is expected to price during the week of December 7, 2020.EMERYVILLE, Calif., (GLOBE NEWSWIRE) - 4D Molecular Therapeutics, Inc. Goldman Sachs, BofA Securities and Evercore ISI are the joint bookrunners on the deal. It plans to list on the Nasdaq under the symbol FDMT. It has two additional candidates that it expects to file INDs for in the 2H21.ĤD Molecular Therapeutics was founded in 2013 and booked $17 million in collaboration and license revenue for the 12 months ended September 30, 2020. Its lead candidates include 4D-125, which is currently in a Phase 1/2 trial for X-linked retinitis pigmentosa with initial data expected in 2021 4D-110, which is currently in a Phase 1 trial for choroideremia with initial data expected in 2022 and 4D-310, which is currently in a Phase 1/2 trial for Fabry disease with initial data expected in 2021. At the midpoint of the proposed range, 4D Molecular Therapeutics would command a fully diluted market value of $491 million.ĤD is developing product candidates using its targeted and evolved AAV vectors, initially focusing on ophthalmology, cardiology, and pulmonology. The Emeryville, CA-based company plans to raise $100 million by offering 4.8 million shares at a price range of $20 to $22. 4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, announced terms for its IPO on Monday.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |